Dansereau Emily, Gakidou Emmanuela, Ng Marie, Achan Jane, Burstein Roy, DeCenso Brendan, Gasasira Anne, Ikilezi Gloria, Kisia Caroline, Masters Samuel H, Njuguna Pamela, Odeny Thomas A, Okiro Emelda A, Roberts D Allen, Duber Herbert C
Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, United States of America.
Department of Pediatrics and Child Health, Makerere University, Kampala, Uganda.
PLoS One. 2015 Aug 14;10(8):e0135653. doi: 10.1371/journal.pone.0135653. eCollection 2015.
Patients receiving antiretroviral therapy (ART) require routine monitoring to track response to treatment and assess for treatment failure. This study aims to identify gaps in monitoring practices in Kenya and Uganda.
We conducted a systematic retrospective chart review of adults who initiated ART between 2007 and 2012. We assessed the availability of baseline measurements (CD4 count, weight, and WHO stage) and ongoing CD4 and weight monitoring according to national guidelines in place at the time. Mixed-effects logistic regression models were used to analyze facility and patient factors associated with meeting monitoring guidelines.
From 2007 to 2012, at least 88% of patients per year in Uganda had a recorded weight at initiation, while in Kenya there was a notable increase from 69% to 90%. Patients with a documented baseline CD4 count increased from 69% to about 80% in both countries. In 2012, 83% and 86% of established patients received the recommended quarterly weight monitoring in Kenya and Uganda, respectively, while semiannual CD4 monitoring was less common (49% in Kenya and 38% in Uganda). Initiating at a more advanced WHO stage was associated with a lower odds of baseline CD4 testing. On-site CD4 analysis capacity was associated with increased odds of CD4 testing at baseline and in the future.
Substantial gaps were noted in ongoing CD4 monitoring of patients on ART. Although guidelines have since changed, limited laboratory capacity is likely to remain a significant issue in monitoring patients on ART, with important implications for ensuring quality care.
接受抗逆转录病毒疗法(ART)的患者需要进行常规监测,以跟踪治疗反应并评估治疗失败情况。本研究旨在找出肯尼亚和乌干达在监测实践方面的差距。
我们对2007年至2012年间开始接受ART的成年人进行了系统的回顾性病历审查。我们根据当时的国家指南评估了基线测量值(CD4细胞计数、体重和世界卫生组织临床分期)的可用性以及持续的CD4细胞计数和体重监测情况。使用混合效应逻辑回归模型分析与符合监测指南相关的机构和患者因素。
2007年至2012年期间,乌干达每年至少88%的患者在开始治疗时有体重记录,而肯尼亚则从69%显著增加到90%。两国记录有基线CD4细胞计数的患者从69%增加到约80%。2012年,肯尼亚和乌干达分别有83%和86%的确诊患者接受了推荐的每季度体重监测,而半年一次的CD4细胞计数监测则不太常见(肯尼亚为49%,乌干达为38%)。在世界卫生组织更晚期别开始治疗与基线CD4检测的较低几率相关。现场CD4分析能力与基线及未来CD4检测几率的增加相关。
在接受ART患者的持续CD4监测方面存在显著差距。尽管此后指南有所变化,但有限的实验室能力可能仍然是监测接受ART患者的一个重大问题,对确保优质护理具有重要影响。